DSP-2230
From Infogalactic: the planetary knowledge core
Jump to: navigation, search
DSP-2230 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
Opioids |
|
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anilines | |||||||||||||||||
NSAIDs |
|
||||||||||||||||
Cannabinoids | |||||||||||||||||
Channelergics |
|
||||||||||||||||
Myorelaxants | |||||||||||||||||
Others | |||||||||||||||||
|
|||||||||||||||||
|
<templatestyles src="Asbox/styles.css"></templatestyles>
![]() |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://infogalactic.com/w/index.php?title=DSP-2230&oldid=712094319"